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Abstract
An improved version of quantitative protein array platform utilizing linear Quantum dot signaling for systematically
measuring protein levels and phosphorylation states is presented. The signals are amplified linearly by a confocal
laser Quantum dot scanner resulting in ~1000-fold more sensitivity than traditional Western blots, but are not
linear by the enzyme-based amplification. Software is developed to facilitate the quantitative readouts of signaling
network activities. Kinetics of EGFRvIII mutant signaling was analyzed to quantify cross-talks between EGFR and
other signaling pathways.
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Background
The emerging field of Systems Biology focuses on the
most daunting challenges in biology and medicine. It is an
attempt to understand how all parts of the cell - genes,
proteins, and other molecules - work in concert to create
complex living organisms and analyzing how entire bio-
logical systems function, both in health and in sickness.
Systems biology always relates big amount of data, which
makes high throughput technologies are crucial. The rapid
advance of high throughput technologies has enabled
scientists to broaden their research from detailed investi-
gation of a few selected genes/proteins to global gene/pro-
tein expression profiles and network analysis. Among the
network analysis, cellular signal transduction networks
play an important role in regulating cellular processes,
such as proliferation, cell growth and death. Proteins are
the work-horses that carry out these functions. Therefore,
it is crucial to capture the dynamics of protein kinases and
post-translational regulations within cellular signal trans-
duction networks for understanding how the signaling
pathways are operated in healthy versus disease
conditions.
Reverse phase protein lysate array (RPPA), originally
introduced by Drs L. Liotta and E. Petricoin [1], is
designed for measuring protein expression in a large
number of biological samples quantitatively. Sample
lysates were spotted in series of dilutions to generate
dilution curves for quantitative measurements. Arrays are
probed with a primary antibody followed by a species-
specific secondary antibody similar to the Western blot.
The detection signal comes from the tag on the second-
ary antibody. A range of detection tags have been devel-
oped including colorimetric, fluorescent, near-infrared
(IRDye), and Quantum dot (Qdot) assays [2-6]. RPPA
has been applied to protein monitoring for biomarker
discovery and/or signal transduction proteins in response
to various biological stimuli or chemical treatments
[7-10]. However, to use RPPA as a quantification assay is
a real challenge, because the linear signals, the founda-
tion of quantification, are difficult to be obtained by
using the common enzyme-based (horseradish peroxi-
dase, HRP) signal amplification systems such as Tyra-
mide Signal Amplification (TSA™, Molecular Probes), or
Catalyzed Signal Amplification (CSA™, Dako) [2-5].
Non-enzyme based signal detection based on IRDye with
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hyperspectral imaging microscope (not commercial avail-
able) [6] have been reported. Here, we report another
alternative non-enzyme amplification approach using
Qdot and commercial available confocal laser Qdot scan-
ner for protein quantification.
The Qdot is a nano-metal fluorophore with bright and
linear signal, and the advantage of using Qdot is it has no
photo-bleaching effect that often occurs while using
organic fluorophores. In combination of confocal laser
Qdot scanner, we present an enhanced version of the
RPPA platform for sensitive, reproducible and quantita-
tive cellular signal transduction network measurements.
The cell lysis buffer is optimized for RPPA printing and
dissolving whole cell proteins without using urea. The
thin-coated-nitrocellulose slide is chosen for strong pro-
tein binding and low fluorescence background. A confo-
cal laser Qdot scanner is utilized to amplify and maintain
the signal linearity. The widely used enzyme-based ampli-
fication is not linear, resulting in nonlinearity signals that
not suitable for the quantification is also demonstrated.
To further reduce background fluorescence from nitro-
cellulose and increase signal/n o i s er a t i o s ,t h ea d v a n t a g e
of using confocal laser is that it can focus Laser right
above the nitrocellulose coating. Integrated software is
used to automatically analyzea r r a yi m a g e s ,q u a l i f ya n d
quantify spots in series, and generate serial dilution
curves to determine the relative protein levels and phos-
phorylation states in the samples.
To demonstrate the capacity of our platform to capture
the dynamics of signaling responses, and determine the
sensitivity to detect minute changes, glioma cancer cells
expressing constitutively activated EGFRvIII mutant under
tetracycline control were analyzed by protein arrays. The
EGFRvIII mutant is a common oncogenic mutant co-
expressed with wild-type EGFR in glioblastoma (GBM)
[12]. EGFRvIII is unable to bind ligand and signals consti-
tutively. Kinetics of signaling after conditional induction of
EGFRvIII expression was analyzed to quantify the
response. The dynamics of pathway interactions (i.e.
cross-talks) between EGFR pathways and other signaling
pathways were then captured.
Results and discussion
Understanding complex cellular systems will require the
identification and analysis of each of its components and
allow determination of how they function together and are
regulated. A critical step in this process is to determine
the biochemical activities of the proteins and how these
activities themselves are controlled and modified by other
proteins. Traditionally, the biochemical activities of pro-
teins have been elucidated by studying single molecules,
one experiment at a time. This process is not optimal, as it
is slow and labor intensive. To obtain a global view of
molecular events instead of individual molecules, we uti-
lize the protein array approach to monitor the molecular
network response.
Linear Dynamics for Quantization
To test the linearity of Qdot signal, we produced cell
lysates with artificial gradient of p53 protein by mixing
null p53 cell lysate (human lung cancer H358 cells with
null p53 gene) and p53 mutant cell lysate (human lung
cancer H2009 cells with overexpressing mutant p53) in
different proportions. Figure 1A is the array image ampli-
fied by confocal Laser scanner. Figure 1B is the array
image amplified by CSA (HRP-based) system. As shown in
Figure 1C, R2 value of the Laser-amplified linear regres-
sion curve is close to 1 indicating Qdot-RPPA can distin-
guish at least 25% change of protein levels within the
linear range, verse the signals of CSA-amplification show-
ing the sigmoid response indicating lost of the linearity.
Sensitivity
In Figure 2, using purified Akt protein, Qdot-RPPA, like
CSA-RPPA, can detect as low as 0.1 pg compared to
0.1 ng of the detection limit using traditional Western
blot in normal conditions, at least 1000-fold more sensi-
tive (Figure 2A vs. C). Moreover, the signal linearity over
serial dilutions makes Qdot-RPPA a reliable tool for
quantification (Figure 2B vs. D).
Specificity
Qdot-RPPA can detect specific kinase activities with
validated phospho-specific antibodies. In Figure 3,
Qdot-RPPA distinguishes phospho-AKT (pAKT ser473)
activation in the PI3 kinase inhibitor (LY294002) vs.
phosphatase inhibitor (Calyculin A) treatments as well
as with vs. without serum stimulation. Total AKT is not
altered during treatment. Thus, with a pair of validated
total and phospho-specific antibodies, Qdot-RPPA can
be used to monitor functional status of a given kinase
under different treatments, or diseases.
Reproducibility
The signals of Qdot are reliable over time. Examples of
ERK protein stain are shown in Figure 4. The same
samples were spotted and hybridized with Qdot at the
different time in duplicate. R
2 values are about 0.95.
Linearity Tests for Phospho-specific Antibodies and
Caspase
In Figure 5, a series of commercial available negative and
positive controls for indicated phospho-specific and cas-
pase 3 antibodies were mixed proportionally to generate
artificial gradients of target proteins: 2A. pAKT; 2B. pERK;
2C. pGSK3; 2D. pNFkB; 2E. pp38; 2F. cleaved caspase 3.
The intensities from 0% gradients were considered to be
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Page 2 of 13non-specific signals from the antibodies, and deducted
from the readouts of other gradients. The Y axis is the
calibrated signal intensity after subtracting the non-speci-
fic background signal. R
2 values of these Laser-amplified
linear regression curves are near 1 assuring that Qdot-
RPPA can distinguish at least 25% change of protein func-
tional levels while using validated antibodies.
Array Image Processing and Statistic Readouts
Compared to commercially available DNA microarrays,
protein arrays present additional challenges in image ana-
lysis. The variety of array formats, spot shapes, and
intensity profiles makes it challenging to extract spot sig-
nals correctly. In addition, the different array substrates,
printing mechanisms and protocols, staining/blocking
processes, and broad applications result in various kinds
of complex images. It is extremely difficult to develop
one algorithm fit all applications. MicroVigene™ is
implemented based on the object-oriented technology
and enable a robust software system integrating with
multiple algorithms that is flexible, configurable as well
as extensible to provide customized solutions, support
any future needs, and adapt along with this emerging
field through proper plug-ins (Figure 6) [13].
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Figure 1 Linearity of Laser-amplified Qdot-RPPA for quantifying protein levels. A. Human H358 (p53 null) lung cancer cell lysate was
mixed with H2009 (p53 mutant) cell lysate proportionally (%) as indicated, then printed with seven serial dilutions in triplicate on protein array.
The array was probed for total p53 levels and signals amplified by a confocal laser Qdot scanner. B. The same lysates in A., but signals amplified
by CSA kit (Dako). C. Linear regression curve of 1:8 dilution from Panel A is shown here. X axis is % of p53 mutant lysate in the mixed sample
and Y axis is the corresponding Qdot intensity corrected with total protein loading, then subtracted the background signal at the 0% of p53.
Black squares is the data from Panel A; red diamond is the data from Panel B. 25% change of p53 can be detected by Laser-amplified Qdot-
RPPA as indicated by the black linear regression line. In contrast, linearity was lost with HRP-amplification shown as a red sigmoid curve.
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Page 3 of 13Customized MicroVigene™ microarray image analysis
software has been developed for high throughput, auto-
matic array image processing and quantitative readouts
from serial dilutions of samples. The software imple-
ments the actual boundary algorithm for spot identifica-
tion/segmentation that is resistant to the spot shift and
image shift (Figure 7); the regional background algo-
rithm for local non-uniform background correction and
sensitive spot quantification (Figure 8).
Also, instead of generating multiple linear regression
curves for data quantification over each series of serial dilu-
tions, MicroVigene™ implements the SuperCurve algo-
rithm (details in the Methods section) [14] that using all
spots within one array to form a sigmoid antigen-antibody
binding kinetic curve (i.e. SuperCurve) (Figure 9A). The
advantage of SuperCurve is the resistance to the experi-
mental outliers or missing spots on the array compared to
regular linear regression curves formed by only a few spots
over a serial dilution. The SuperCurve is a consensus curve
supported by all spots on the array. This process has been
implemented into the automatic data analysis workflow
after the spot identification to automatically generate a
reaction curve for each antibody as well as the quantitative
readouts from each dilution series.
The automatic dust finding and removal algorithm is
also implemented to increase the accuracy of curve fit-
ting and the intensity readouts. In Figure 9B, a small
but intensified dust spot was automatically detected in
the lowest dilution spot, and then visualized by 3D
image manually. Without the dust removal, the spot was
flagged as an outlier of the SuperCurve verse, after
removing the dust signal, the spot fitted in the Super-
Curve well (Figure 9C).
In summary, these unique features of MicroVigene™
make it capable of handling shifted and noisy protein
array images and enabling the hand-free batch process
required for high throughput protein array image
processing.
The Dynamics of EGFRvIII Signaling Network
Effective targeted treatment of glioblastoma (GBM) may
require a coordinated inhibition of multiple signals.
Much remains to be learned about functional interac-
tions among signal transduction networks in GBM. For
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Figure 2 Sensitivity and linearity of Qdot-RPPA. A. Qdot-RPPA could detect as low as 0.1pg of purified AKT. From top to bottom are 10 serial
dilutions. From left to right represent 10 replicates. The Signal/Noise ratios are from 30 to 150 as indicated. B. The linearity of the intensity. X-axis
indicates the exponent of 2-fold serial dilution and Y-axis represents the relative intensity normalized to the highest concentration. C. The
corresponding Western blot showing the detection limit is 0.1ng, a 1000× difference in sensitivity. D. The signals of the Western blot were
quantified from film and graphed as in B. The sigmoid curve indicates signal saturation and low dynamic range using Western blot.
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Figure 4 Reproducibility of Qdot-RPPA. The same samples were spotted two months apart, and probed with ERK antibody. A. The scatter
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Page 5 of 13example, GBMs express multiple receptor tyrosine
kinase (RTK) families and ligands. Increasing evidence
suggest extensive cross-talking between RTK signaling
networks that have functional implications for multi-tar-
get treatment. EGFRvIII is a common oncogenic mutant
that is co-expressed with the wild-type EGFR in GBM.
We applied Qdot-RPPA to investigate key protein regu-
lators and kinases (total 61 antibodies listed Table 1)
that are altered by conditional inducible EGFRvIII in
U87MG glioma cell line. The dynamics of pathway
interactions (i.e. cross-talks) among canonical EGFR
pathway, Akt, Src and JNK pathways after turning on
the EGFR vIII were captured (Figure 10). Qdot-RPPA
detected the total EGFR, pEGFR and pERK levels
changes within one to six hours after adding tetracy-
cline; Activation of Akt [15,16], Src [17,18] and JNK
[19-21] happened at later time (20-24 hrs), and, interest-
ingly, pSrc (52.8×) and pJNK (4.4×) were activated at
much higher levels than the downstream pERK (3.8×) in
the canonical pathway (Array images shown in Figure
10 and fold change in activity shown in Table 2). The
results suggest the selection of potential candidates for
the future multi-target treatment in GBM, e.g. co-target-
ing EGFRvIII and Src/JNK kinases for cancer treatment
[17,18] since Src and JNK activities are elevated much
higher than ERK over time.
Conclusions
In conclusion, we have established a quantitative proteo-
mic technology - Qdot-RPPA platform, in conjunction
with the emerging Quantum dot (Qdot) nanotechnology,
a confocal laser scanner, computer automated array image
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Figure 5 The Linearity tests for Quantifying Cellular Signaling Kinases. A series of negative (-) and positive (+) controls for phospho-specific
and caspase 3 antibodies were mixed proportionally to generate artificial gradient of target proteins for the linearity tests using laser-amplified
Qdot-RPPA. Examples shown here are (A) pAKT, (B) pERK, (C) pGSK3, (D) pNFkB, (E) pp38, (F) cleaved caspase 3. pAKT+, pERK+ and pGSK+ are
Jurkat cells treated with phosphatase inhibitor, calyculin A, to accumulate these kinases in phosphorylated states. pNFkB+ is HeLa cells stimulated
with TNF (20 ng/ml, 5 min) to activate NFkB. p-p38+ is C6 glioma cells treated with anisomycin to activate p38. Cleaved caspase 3+ is
cytochrome c treated Jurkat cell lysates to induce the cleavage of caspase 3. X axis is the gradient (25% intervals) of targeted protein. Y axis is
the calibrated signal intensity after subtracting the background signal at the 0% gradient. R
2 values of linear regression curves close to 1 indicate
laser-amplified Qdot-RPPA can distinguish at least 25% change of protein levels within the linear range. Error bars were derived from the three
replicates of each sample.
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Page 6 of 13analysis to generate quantitative outputs. This platform
eliminates the signal non-linearity causing by enzyme-
amplification, while still keeps the advantages of RPPA
such as: minute sample per spot(~1nl); high sensitivity
(~0.1 pg); high specificity with validated antibodies; high
reproducibility; and large capacity of spots on one slide
allowing investigating a large number of experimental con-
ditions in parallel within one array.
The primary contribution of our Qdot-RPPA platform
is to take advantage of Qdot linear signal with no photo-
bleaching and large dynamic range for quantification by
utilizing confocal Laser Qdot scanner. This technology
not only offers us the capacity to quantitatively monitor
the time series and dose responses of cellular response
over signaling network after treatments or different dis-
ease stages, but also facilitates the complex functional
analysis among different signaling pathways. We also
found that thin coated (10 um) nitrocellulose slide with
scanning Laser focus above the coating yields low fluor-
escence background and increases signal/noise ratio.
We have applied Qdot-RPPA platform to study the
Dynamics of EGFRvIII Signaling Network with 61 antibo-
dies. The results demonstrated this platform worked well
to reveal not only the dynamics of canonical pathway but
also cross-talks among pathways. The ultimate goal is to
extend this platform with more validated antibodies to
provide high sample throughput functional protein data to
compliment DNA based genomics array data for systems
biology analyses, and provide direction for more in-depth
experimentation prediction and hypothesis generation.
Methods
Cell Lysate Preparation
p53 control cell lysates were prepared from human H358
(p53 null) lung cancer cells and H2009 (p53 mutant)
cells. The rest of control cell extracts were purchased
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Figure 6 Software Architecture of MicroVigene™for High Throughput Protein Microarray Analysis. MicroVigene™ integrates protein array
image analysis and statistical signal data analyses in a single automated process. The array images are analyzed in a batch process. Data analyses
including background correction, statistics of replicates, dilution curve fitting, quality controls, normalization can be carried out automatically. The
final outputs are the EC50 values from each serial dilution arranged in a spread sheet that can be further analyzed by other Bioinformatics tools.
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Page 7 of 13from Cell Signaling Technology: Akt (cat# 9273), p38
MAP kinase (cat# 9213), NF-B (cat# 9243), and cas-
pase-3 (cat# 9663). Purified Akt protein was purchased
from Invitrogen (cat# P2999). U87MG glioma cells were
stably transfected with an EGFRvIII mutant using a tetra-
cycline inducible system as described previously [22].
Cells were treated with tetracycline (1 ug/ml), and then,
harvested at 0, 6, 20, 24 and 48 hours, respectively. The
following cell lysis protocol is optimized to harvest total
cell proteins including hard-to-dissolved membrane pro-
teins without using Urea. Cells were washed twice in cold
phosphate buffered saline (PBS) and subsequently lysed
in 250-350 μL hot lysis buffer (2% SDS; 0.06 M Tris-Cl,
pH 6.8; 5% Glycerol). Proteinase inhibitor (Sigma,
cat# P8340) and phosphotase inhibitor cocktails (Santa
Cruz Biotechnology, sc-45044 and sc-45045) and 2%
b-mercaptoethanol were freshly added before use. The
cellular lysates were boiled for 5 min on heat block, fol-
lowed by 1 min vortexing, and then centrifuged at 13,000
rpm for 7 min at 4°C. Cells should be completely dis-
solved without much precipitates left at this step. Super-
natants were transferred to new tubes and stored at
-20°C. Protein concentration was measured using Brad-
ford assay (Bio-Rad, cat# 500-0006). All the samples were
adjusted to 0.5 ug/uL as the highest concentration on the
arrays. However, to correct for protein loading, Sypro
Ruby™ protein stain signals were used as described
below.
Figure 7 Actual Boundary and Flexible Grid Algorithms.I m a g e
and spot shifts among arrays are the major challenge for the
automation of array image processing. The fixed spot grid cannot be
applied to all images. The actual boundary and flexible grid algorithms
are designed to make spot boundary and grid flexible enough to
compensate the shifts. These algorithms are essential for the successful
automation of array image analysis using MicroVigene™.
Original Spot Image
Regional
Background Image
Background 
Corrected Spot Image
A. B. C.
Figure 8 Regional Background Correction Algorithm. This algorithm is to correct the original spot signal intensity (A) with local background
(B). The real spot signals (C) can be extracted. Four spots within the black dashed square boxes in 2D view are shown in the 3D view windows
below. This algorithm improves accuracy, consistency, and sensitivity for image processed using MicroVigene™.
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Page 8 of 13Qdot-Reverse-Phase Protein Microarray (Qdot-RPPA)
Protein lysates were filtered through 96-well filter plate
with 25 μm pore membrane (Phenix Research Products,
cat# MPF-009) by centrifuge to remove sticky aggregates,
and serially diluted (1:2) 4 times using 1 × lysis buffer.
Lysates were arrayed on ONCYTE
® AVID nitrocellulose
film slides (Grace Bio-Labs, cat# 305170) using a SpotAr-
ray™24 Microarray printing system (PerkinElmer) with
55-60% humidity. Spots were separated with 350 μm
space in between. Approximately 1 nl of lysate per spot
was arrayed using 4 spotting pins (TeleChem/ArrayIt,
cat# 946MP3). Slides were dried at RT for about 30 min,
and then stored at 4°C. Immuno-staining was performed
within one week. We have tested various slides from
different vendors. The AVID slides were chosen due to
its high protein binding capacity with less protein lost,
and thin-coated (10 micron) nitrocellulose film with less
auto-fluorescence background, suitable for both Qdot™
and SyproRuby™ stains.
Laser-amplified Qdot-RPPA and Immuno-staining
The slides were placed into four-chamber plates (ISC
Bioexpress, cat# T-2896-1) and incubated at room tem-
perature in Re-blot Plus Mild Solution (CHEMICON, cat#
2502) for no more than 7 minutes to relax protein struc-
ture. After the Re-blot was removed, the slides were
washed 5 min three times in TBS-T buffer (2.42 g Tris-
HCl, 16 g NaCl in 1 L dH2O, 0.1% Tween-100, pH 7.6).
* *
Beforedustremoval After
B. A.
C.
LinearRegression
SuperCurve
Figure 9 Automation of Qdot-RPPA Image and Data Analysis. Several features of MicroVigene™ software are to facilitate the automatic
batch process. A. Super Curve: Instead of generating multiple linear regression curves for each serial dilution, the Super Curve algorithm uses all
spots on the same array to fit one antigen-antibody reaction curve (called Super Curve, the red line) for the quantitative readouts. The purple
lines indicate error boundary. B. 2D and 3D views of the actual spot boundary algorithm for actual spot identification and dust finding (indicated
by asterisk); the total intensity within the defined spot boundary (i.e. volume) was used for Super Curve fitting. C. Screen shots of the dust
removal feature. Left: before removing the dust, the spot is flagged as an outlier (the red spot pointed by the arrow). Right: after dust removal,
the spot fits the Super Curve.
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Page 9 of 13The slides were incubated in Sea Block blocking buffer
(Thermo, cat# 37527) at 4°C overnight, and then blocked
with Avidin and Biotin (Dako, Biotin blocking system cat#
X0590) sequentially. Between steps, slides were washed
with TBS-T buffer. After the blocking, the slides were
incubated with primary antibodies (diluted in antibody
diluent buffer, Dako, cat# S3022) at 4°C overnight. We
used 61 validated primary antibodies listed in the Table 1
and the Additional file 1; validation information is in [3].
Next, slides were washed with TBS-T buffer, and incu-
bated with biotinylated secondary antibodies (Vector, anti-
rabbit BA-1000 or anti-mouse BA-9200 IgG) (1:5000) for
30 min, then with Qdot 655-streptavidin conjugate (Invi-
trogen, cat# Q10121MP) for 30 min. Qdot were diluted
1:200 in boric acid buffer (50 mM Borate, 2% BSA, pH
8.3). The slides were washed with TBS-T buffer 3 times,
and MilliQ water once and then briefly spun at 2000 rpm
for 5 min to dry the slides. To detect Qdot signals, slides
were scanned with full Laser power on a ProScanArray
Microarray Scanner (PerkinElmer), and the Laser was
focused 10 micron above the slide surface. The excitation
wavelength was set at 488 nm and emission wavelength
was set at 655 nm using a Qdot 655 filter. Images were
saved in 16-bit TIFF format and the maximum signal
intensity was 65535.
Enzyme-based Qdot-RPPA
Qdot-RPPA using the Tyramide and horseradish peroxi-
dase (HRP) amplification system (Dako CSA™ system,
cat# K1500) to amplify the Qdot signal was previously
described [5,6]. This protocol was performed for the
comparison shown in Figure 1B.
Automatic Array Image analysis and Quantification
Scanned TIFF images were batch-analyzed using MicroVi-
gene™ software (VigeneTech inc. http://www.vigenetech.
com/). In RPPA, cell lysates were printed on the arrays.
Each array is probed with one specific primary antibody
and scanned for one image. It is necessary to have compu-
ter-aid image analysis that can process array images auto-
matically to increase the throughput of the number of
antibodies one can apply. This work was done in colla-
boration with VigeneTech, Inc., a leader of developing
automated image analysis technology. MicroVigene™ pro-
vided unique software customized to analyze the Qdot-
RPPA platform. Unique features of the software provide
accuracy, sensitivity, and reliable results of automation
[13] including flexible grid and actual spot boundary algo-
rithm to quantify spot signals accurately; dust removal
algorithm to remove the contaminated signals; regional
background algorithm for local non-uniform background
correction and sensitive spot quantification. Ten thousand
spots can be processed in less than one minute and, with
the feature of hands-free batch processing, MicroVigene™
enables the high throughput protein array image analysis.
3D visualization of processed images is also available for
manually quality assurance.
Each sample has five dilutions and was printed in tri-
plicate on the array. Therefore, each dilution series has
total of 15 data points to minimize errors and increase
the confidence of curve-fitting. Instead of generating
multiple linear regression curves for data quantification
over each series of serial dilutions, MicroVigene imple-
ments the SuperCurve algorithm (a 4-parameter logis-
tic-log model, i.e. parameters a-d shown in equation
below) that uses all spots within one array to form a sig-
moid antigen-antibody binding kinetic curve (i.e. Super-
Curve) [14].
Y=a+
(b -a )

1+e (c*(d-l n (x)))
where x is the dilution factor and Y is the signal
intensity. The signal readout of each dilution series is
the intensity of EC50 from the fitted SuperCurve. The
assumption is that the same antibody-antigen binding
kinetics is taking place at each sample spot, even in the
different samples, thus by taking all spots on an array to
fit a common response curve can increase the confi-
dence of the curve fitting.
Calibration for protein loading was based on total pro-
tein per spot. For estimation of total protein amounts,
randomly selected arrays were stained with Sypro
Table 1 Current Available Validated Antibodies for
Protein Kinases and Regulators
AKT Rb NFkBp65
pAKT(S473) pRb(S807_811) pNFkBp65(S536)
pAKT(T308) p16 IKBa
ERK1/2 p21 pIKBa(S32)
pERK1/2(S44/42) p27 MDM2
GSK3ab CyclinB1 pMDM2(S166)
pGSK3ab(S21/9) CyclinD3 E-Cadherin
IRS1 Cdk4 Vimentin
pIRS1(Y896) EGFR b-Catenin
pIRS1(Y1179) pEGFR(Y1173) gH2AX
mTOR IGF1R Hsp27
pmTOR(S2448) pIGF1R(Y1158_1162) NQO1
PTEN pIGF1R(Y1162_1163) sClu
pPTEN(S380) Raf1 b-Actin
p38 pRaf1(S259) Smad3
pp38(T180_Y182) Bcl2 pSmad3(S423/425)
Src pBcl-2(S70) Cleaved Caspase 3
pSrc(Y416) JNK Cleaved Caspase 8
pSrc(Y527) pJNK(T183_185) Cleaved Caspase 9
Stat3 p53
pStat3(S727) pp53(S15)
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Page 10 of 13Ruby™ (Invitrogen, cat# S11791), and visualized on
ProScanArray Scanner (PerkinElmer) with excitation
wavelength at 450 nm and emission wavelength at 610
nm. The corrected values were calculated by dividing
the EC50 readouts of the antibody to the corresponding
EC50 readouts of the Sypro Ruby™ stain. In Figure 5,
the 0% positive gradient on the left was considered as a
non-specific signal from the antibody, and deducted
from the readouts of other gradients. In Figure 10, the
intensity of time point 0 was treated as a baseline and
relative fold change of activity at the other time points
were compared to time 0.
TetͲon(hr)
016202448
Row2:TetͲonEGFRvIII
pEGFR
(Y1173)
pERK1/2(S44/42)
pJNK(T183_85) pRaf1(S259) pSrc(Y416)
TotalProteinLoading
pͲp38(T180Y182) pNFkBp65(S536)
1:1
1:2
1:4
1:8
1:16
U1GliomaCellline
Row1:Vectorcontrol
pAKT(S473)
Total
EGFR
Row3Ͳ10:1:2serialdilutions
12345
CrossͲTalks
FoldChange
ofKinaseActivity
Figure 10 Signaling network up-regulated by constitutively activated EGFRvIII mutation. U87MG glioma cells were transfected with a
conditional inducible tetracycline (tet-on) sytem. A EGFRvIII expressing line (row 2) as well as vector control (row 1) was treated with
tetracycline (1 ug/ml) for 0, 1, 6, 20, 24 and 48 hours as indicated. Activities of signaling kinases were monitored by Qdot-RPPA. Each sample
was serially diluted 1:1 to 1:16 for quantification and spotted in triplicate on the arrays, then probed with total and phospho-specific kinase
antibodies. Relative fold changes to time 0 were quantified and illustrated with color under each corresponding array images. Black arrows
indicate known canonical signaling pathways; Red dashed arrows indicate the cross-talks between Akt, Src and JNK pathways. p38 and NFkB
stay inactive.
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Page 11 of 13Additional material
Additional file 1: Antibodies used for Qdot-Reverse Phase Protein
Array. Detail information of antibodies used.
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